Senseonics (SENS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
The annual meeting is scheduled for May 20, 2026, and will be held virtually, allowing shareholders to participate online, submit questions, and vote electronically.
Shareholders will vote on director elections, executive compensation, auditor ratification, an increase in authorized shares, and a new equity incentive plan.
The record date for voting eligibility is March 26, 2026, with 41,795,466 shares outstanding.
Voting matters and shareholder proposals
Six proposals are up for vote: election of three directors, advisory approval of executive compensation, advisory vote on frequency of say-on-pay, ratification of KPMG LLP as auditor, amendment to increase authorized shares, and approval of the 2026 Equity Incentive Plan.
The board recommends voting for all director nominees, for executive compensation, for annual say-on-pay votes, for auditor ratification, for the share increase, and for the new equity plan.
Shareholders can vote online, by phone, mail, or during the virtual meeting; beneficial owners must follow broker instructions.
Board of directors and corporate governance
The board is divided into three classes, each serving staggered three-year terms; six of nine directors are independent.
Leadership structure separates the roles of Chairman and CEO, with an independent chairman presiding.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Directors are encouraged but not required to attend the annual meeting; all attended in 2025.
Stockholders can communicate with the board via a formal process; a code of ethics and corporate governance guidelines are in place.
Latest events from Senseonics
- 2025 revenue up 60% to $35.3M; 2026 guidance: $58–$62M and >50% gross margin.SENS
Q4 20252 Mar 2026 - 2025 guidance projects $34–38M revenue and a doubling of the global patient base.SENS
Q4 202413 Feb 2026 - Q2 2025 revenue up 37% YoY to $6.6M, gross margin at 46.9%, net loss narrowed to $14.5M.SENS
Q2 20253 Feb 2026 - Launching a one-year CGM sensor and expanding partnerships to capture rapid diabetes market growth.SENS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 18% year-over-year, but losses and funding risks remain as Q4 launch nears.SENS
Q2 20242 Feb 2026 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 202415 Jan 2026 - 365-day CGM launch drives record leads and sets stage for growth with new partnerships and innovations.SENS
Stifel 2024 Healthcare Conference13 Jan 2026 - Up to $300M in securities offered to fund CGM growth, with high risk and dilution potential.SENS
Registration Filing16 Dec 2025 - Registration enables resale of 45.7M shares tied to long-term CGM innovation and key partner reliance.SENS
Registration Filing16 Dec 2025